Series E · Biotech
Circle Pharma raises $92.5M Series E for macrocycle drug programs
Its MXMO platform aims to produce cell-permeable macrocycles for cancer and other serious diseases.
Designing drugs for hard-to-reach targets
Circle Pharma’s MXMO platform combines structure-based design with chemistry to create macrocycle compounds that can enter cells and engage disease-driving proteins. The company is advancing investigational programs in oncology and other serious illnesses, where many targets have been difficult for conventional small-molecule drugs to address.
Use of funds
Expand operations and research and development
Funding history
Series E · This round$92.5M